The Stratified Population Screening of Hereditary Hemorrhagic Telangiectasia.
Autor: Major, Tamás; Gindele, Réka; Szabó, Zsuzsanna; Kis, Zsuzsanna; Bora, László; Jóni, Natália; Bárdossy, Péter; Rácz, Tamás; Bereczky, Zsuzsanna
Publication year: 2020
Pathology oncology research : POR
issn:1532-2807 1219-4956
doi: 10.1007/s12253-019-00602-7
Abstract:
Hereditary hemorrhagic telangiectasia (HHT) is an autosomal dominant multisystemic vascular disease with a wordwide prevalence of 1:5000-1:10000. We introduce our algorithm for the stratified population screening of HHT. Probands are selected from the consecutive hospital database review for HHT (I7800) and recurrent epistaxis (R0400) and the review of patient records referred by family practicioners. A proportion of probands might be de novo diagnosed with HHT in the 10-year study period. The checkup of probands consists of physical examination, arteriovenous malformation exploration and and genetic testing (ACVRL1 and ENG sequence analysis). The family screening of HHT consists of physical examination and screening for the family-specific mutation of each at-risk individual, and furthermore, arteriovenous malformation exploration in individuals with suspected/definite HHT and/or carrying the mutation. Twenty-five definite HHT patients were explored: 7 of them by the I7800 review, 1 by the R0400 review, 3 were de novo diagnosed, and the remaining 14 were explored by the systematic family screening. Considering the 20 patients alive at the end of the study period and the unavailable 5 potential HHT patients and 12 at-risk family members, the HHT prevalence is estimated to be 1:6090-1:11267 in our study area, implying our algorithm’s effectivity in the stratified population screening of HHT.
Language: eng
Rights:
Pmid: 30685840
Tags: Humans; Aged; Aged, 80 and over; Female; Male; Adult; Middle Aged; Child; Infant; Follow-Up Studies; Prognosis; Prevalence; *Mutation; Mass Screening/*methods; *Population Surveillance; Genetic Testing; Pedigree; Activin Receptors, Type II/*genetics; ACVRL1; Biomarkers/*analysis; Endoglin/*genetics; ENG; Founder effect; Hereditary hemorrhagic telangiectasia; Stratified screening; Telangiectasia, Hereditary Hemorrhagic/*diagnosis/genetics
Link: https://pubmed.ncbi.nlm.nih.gov/30685840/
